MEDP vs. MRNA: Medpace vs. Moderna Stock Comparison

Company Profile

Medpace (MEDP) and Moderna (MRNA) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but MEDP is classified in Life Sciences Tools & Services while MRNA is classified in Biotechnology.

Price Performance

Cumulative Growth

Trailing Returns

Calendar-Year Returns

Performance Metrics

Risk Profile

Drawdown History

Return Distribution

Risk Metrics

Moderna (MRNA) is heavily traded at around 21.61M shares per day, whereas Medpace (MEDP) sees a more moderate 258.39K — larger orders in the latter may require more patience and tighter control over order sizing.

Risk-Adjusted Performance

Risk-Return Positioning

Risk-Adjusted Metrics

Profitability

Moderna (MRNA) reports a negative ROE of -39.00%; negative ROE can reflect losses or negative shareholders’ equity, so it is harder to read as capital efficiency. Meanwhile Medpace (MEDP) reports 117.88%, ranking against industry peers normally.

Moderna (MRNA) reports a negative net margin of -141.43%, usually indicating a net loss over the period. Meanwhile Medpace (MEDP) reports 18.24%, ranking against industry peers normally.

Moderna (MRNA) reports a negative operating margin of -557.93%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Medpace (MEDP) reports 23.12%, ranking against industry peers normally.

Profitability Metrics

Growth

Medpace (MEDP) at 19.97% is around its peer norm for revenue growth, while Moderna (MRNA) at -39.92% drops into the bottom quartile, signaling weaker demand or pricing momentum.

Only one side can be read here: Medpace (MEDP) reports EPS growth of 20.98%, ranked against its industry; Moderna (MRNA) has no EPS growth figure this period.

Growth Metrics

Financial Strength

Both Medpace (MEDP) at 0.83 and Moderna (MRNA) at 2.30 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

Both Medpace (MEDP) at 0.29 and Moderna (MRNA) at 0.19 fund their balance sheets with roughly industry-typical debt-to-equity mixes.

Financial Strength Metrics

Dividends

Neither Medpace (MEDP) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Neither Medpace (MEDP) nor Moderna (MRNA) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

Dividend Metrics

Valuation

An earnings multiple is available for just one side: Medpace (MEDP) trades at 36.26 times trailing earnings, ranked against its peers, while Moderna (MRNA) has no P/E ratio this period.

Medpace (MEDP) at 6.44 is priced about in line with its industry on P/S ratio, while Moderna (MRNA) at 45.55 sits in the pricier quartile — MRNA costs more per dollar of sales.

Both look rich against book: Moderna (MRNA) at 11.58 sits in the upper P/B ratio quartile, and Medpace (MEDP) at 31.23 prices even higher, above its industry range.

Valuation Metrics